CHMP recommendation expands Roche's Ocrevus market potential to pediatric patients with relapsing MS
Executive summary: The CHMP has issued a positive opinion for Roche's Ocrevus (ocrelizumab) for the treatment of children and adolescents with relapsing multiple sclerosis. This expansion allows Roche to target a younger patient demographic, potentially increasing market share and long-term revenue for the drug.
Who is involved: Roche, CHMP (EMA)
Likely next: Formal European Commission decision to grant marketing authorization.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended extending Roche's Ocrevus (ocrelizumab) to treat children and adolescents with relapsing forms of multiple sclerosis, marking the first regulatory endorsement of a B-cell-depleting therapy for pediatric MS in the EU. The opinion rests on Phase III data demonstrating comparable safety and efficacy to adult populations, addressing a significant therapeutic gap where treatment options have been limited to off-label use of older agents or interferon beta. For Roche, the recommendation arrives at a pivotal moment. Ocrevus generated CHF 5.8 billion in 2023 sales but faces looming biosimilar erosion in key markets later this decade. Securing a pediatric indication extends the franchise's exclusivity runway and reinforces its positioning as the standard-of-care across the MS spectrum, particularly as competition intensifies from newer high-efficacy agents such as Kesimpta and emerging BTK inhibitors. The intravenous formulation's twice-yearly dosing also offers adherence advantages in adolescents compared with daily oral therapies. The European Commission typically formalizes CHMP opinions within two months, after which national health technology assessment bodies will determine reimbursement. Given the high unmet need and existing adult prescribing momentum, uptake in pediatric neurology centers is likely to be rapid, though real-world evidence generation will be closely monitored to confirm long-term safety in developing immune systems.
What's next — scenarios
Base Case: Full EU Approval (75%)
Ocrevus gains access to the pediatric relapsing MS market in the EU, boosting Roche's immunology portfolio.
- European Commission formal ratification
Downside: Restricted Labeling (25%)
Approval granted but with specific age or health condition constraints, limiting market expansion.
- Additional safety data requirements from EMA
What to watch
- European Commission official decision following CHMP recommendation
Timeline
- — CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis (GlobeNewswire)
- — Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness) (GlobeNewswire)
- — POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA VOR ERSTEM HERZINFAKT ODER SCHLAGANFALL (PR Newswire)
Analysis — what this means
Sectors affected
- biotechnology
- pharmaceutical manufacturing
- pediatric neurology
Regulatory implications
- EMA formal marketing authorization for pediatric indications
Historical parallels
- CHMP recommendation for Novo's Sogroya for idiopathic short stature
Key entities
Sources
- CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis — GlobeNewswire
- Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness) — GlobeNewswire
- POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA VOR ERSTEM HERZINFAKT ODER SCHLAGANFALL — PR Newswire
Related cases
- Zealand Pharma secures major regulatory milestone with positive CHMP opinion for Zeydovio in short bowel syndrome treatment
- CHMP recommends EU approval for NewAmsterdam’s obicetrapib therapies, paving potential market entry
- CHMP's positive opinion clears path for NewAmsterdam and Menarini to launch obicetrapib-based cholesterol therapies in Europe